
Inventiva S.A. (IVA) Stock Forecast & Price Target
Inventiva S.A. (IVA) Analyst Ratings
Bulls say
Inventiva SA is focused on developing lanifibranor, a promising candidate for treating non-alcoholic steatohepatitis (NASH), with the potential to benefit a specific patient group: T2D positive MASH patients, who are seen as a particularly viable market. The Phase II NATIVE study has demonstrated lanifibranor's anti-fibrotic effects, reinforcing the drug's potential value in a high-demand area lacking approved therapies. Furthermore, the company's significant revenue from research partnerships with major pharmaceutical companies like AbbVie and BI underscores its strong position within the biopharmaceutical landscape.
Bears say
Inventiva SA is a biopharmaceutical company focused on developing therapies for conditions such as NASH, with its primary product candidate, lanifibranor, currently in Phase III clinical trials. There are concerns regarding high turnover in key regulatory roles, particularly the CEO and CMO, which may adversely affect the company's stability and share performance. Additionally, any efficacy or safety issues arising from lanifibranor during its clinical development could significantly undermine investor confidence and exacerbate the negative outlook on the stock.
This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.
Inventiva S.A. (IVA) Analyst Forecast & Price Prediction
Start investing in Inventiva S.A. (IVA)
Order type
Buy in
Order amount
Est. shares
0 shares